[P1]	O
PF-06439535	O
[P2]	O
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
Reference	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
,	O
Both	O
Plus	O
Paclitaxel	O
and	O
Carboplatin	O
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O

PF-06439535	O
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
[P1]	O
Reference	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
[P2]	O
,	O
Both	O
Plus	O
Paclitaxel	O
and	O
Carboplatin	O
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O

PF-06439535	O
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
Reference	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
,	O
Both	O
Plus	O
[P1]	O
Paclitaxel	O
and	O
Carboplatin	O
[P2]	O
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O

A	O
Randomized	O
,	O
Double	O
-	O
Blind	O
Study	O
[P1]	O
PF-06439535	O
[P2]	O
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
Reference	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
,	O
Both	O
Plus	O
Paclitaxel	O
and	O
Carboplatin	O
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O

A	O
Randomized	O
,	O
Double	O
-	O
Blind	O
Study	O
PF-06439535	O
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
[P1]	O
Reference	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
[P2]	O
,	O
Both	O
Plus	O
Paclitaxel	O
and	O
Carboplatin	O
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O

A	O
Randomized	O
,	O
Double	O
-	O
Blind	O
Study	O
PF-06439535	O
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
Reference	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
,	O
Both	O
Plus	O
[P1]	O
Paclitaxel	O
and	O
Carboplatin	O
[P2]	O
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O

[P1]	O
PF-06439535	O
[P2]	O
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
Reference	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
,	O
Both	O
Plus	O
Paclitaxel	O
and	O
Carboplatin	O
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O

PF-06439535	O
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
Reference	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
,	O
Both	O
Plus	O
[P1]	O
Paclitaxel	O
and	O
Carboplatin	O
[P2]	O
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O

[P1]	O
PF-06439535	O
[P2]	O
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
Reference	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
,	O
Both	O
Plus	O
Paclitaxel	O
and	O
Carboplatin	O
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O

PF-06439535	O
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
Reference	O
[P1]	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
[P2]	O
,	O
Both	O
Plus	O
Paclitaxel	O
and	O
Carboplatin	O
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O

PF-06439535	O
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
Reference	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
,	O
Both	O
Plus	O
[P1]	O
Paclitaxel	O
and	O
Carboplatin	O
[P2]	O
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O

Japan	O
Ishikawa	O
Japan	O
[P1]	O
PF-06439535	O
[P2]	O
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
Reference	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
,	O
Both	O
Plus	O
Paclitaxel	O
and	O
Carboplatin	O
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O

Japan	O
Ishikawa	O
Japan	O
PF-06439535	O
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
Reference	O
[P1]	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
[P2]	O
,	O
Both	O
Plus	O
Paclitaxel	O
and	O
Carboplatin	O
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O

Japan	O
Ishikawa	O
Japan	O
PF-06439535	O
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
Reference	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
,	O
Both	O
Plus	O
[P1]	O
Paclitaxel	O
and	O
Carboplatin	O
[P2]	O
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O

We	O
conducted	O
the	O
current	O
study	O
(	O
B7391003	O
)	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
[P1]	O
PF-06439535	O
[P2]	O
plus	O
paclitaxel	O
and	O
carboplatin	O
with	O
that	O
of	O
bevacizumab	O
-	O
EU	O
plus	O
paclitaxel	O
and	O
carboplatin	O
in	O
the	O
first	O
-	O
line	O
treatment	O
of	O
advanced	O
non	O
-	O
squamous	O
NSCLC	O
.	O

We	O
conducted	O
the	O
current	O
study	O
(	O
B7391003	O
)	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
PF-06439535	O
plus	O
[P1]	O
paclitaxel	O
and	O
carboplatin	O
[P2]	O
with	O
that	O
of	O
bevacizumab	O
-	O
EU	O
plus	O
paclitaxel	O
and	O
carboplatin	O
in	O
the	O
first	O
-	O
line	O
treatment	O
of	O
advanced	O
non	O
-	O
squamous	O
NSCLC	O
.	O

We	O
conducted	O
the	O
current	O
study	O
(	O
B7391003	O
)	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
PF-06439535	O
plus	O
paclitaxel	O
and	O
carboplatin	O
with	O
that	O
of	O
[P1]	O
bevacizumab	O
[P2]	O
-	O
EU	O
plus	O
paclitaxel	O
and	O
carboplatin	O
in	O
the	O
first	O
-	O
line	O
treatment	O
of	O
advanced	O
non	O
-	O
squamous	O
NSCLC	O
.	O

We	O
conducted	O
the	O
current	O
study	O
(	O
B7391003	O
)	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
PF-06439535	O
plus	O
paclitaxel	O
and	O
carboplatin	O
with	O
that	O
of	O
bevacizumab	O
-	O
EU	O
plus	O
[P1]	O
paclitaxel	O
and	O
carboplatin	O
[P2]	O
in	O
the	O
first	O
-	O
line	O
treatment	O
of	O
advanced	O
non	O
-	O
squamous	O
NSCLC	O
.	O

details	O
of	O
the	O
changes	O
can	O
be	O
found	O
in	O
This	O
comparative	O
clinical	O
study	O
was	O
designed	O
to	O
demonstrate	O
that	O
there	O
are	O
no	O
clinically	O
meaningful	O
differences	O
in	O
the	O
efficacy	O
and	O
safety	O
profile	O
of	O
[P1]	O
PF-06439535	O
[P2]	O
(	O
a	O
bevacizumab	O
biosimilar	O
)	O
as	O
compared	O
with	O
reference	O
bevacizumab	O
(	O
Avastin	O
®	O
)	O
sourced	O
from	O
the	O
EU	O
(	O
bevacizumab	O
-	O
EU	O
)	O
in	O
a	O
patient	O
population	O
for	O
which	O
reference	O
bevacizumab	O
is	O
indicated	O
.	O

details	O
of	O
the	O
changes	O
can	O
be	O
found	O
in	O
This	O
comparative	O
clinical	O
study	O
was	O
designed	O
to	O
demonstrate	O
that	O
there	O
are	O
no	O
clinically	O
meaningful	O
differences	O
in	O
the	O
efficacy	O
and	O
safety	O
profile	O
of	O
PF-06439535	O
(	O
a	O
bevacizumab	O
biosimilar	O
)	O
as	O
compared	O
with	O
reference	O
[P1]	O
bevacizumab	O
[P2]	O
(	O
Avastin	O
®	O
)	O
sourced	O
from	O
the	O
EU	O
(	O
bevacizumab	O
-	O
EU	O
)	O
in	O
a	O
patient	O
population	O
for	O
which	O
reference	O
bevacizumab	O
is	O
indicated	O
.	O

details	O
of	O
the	O
changes	O
can	O
be	O
found	O
in	O
This	O
comparative	O
clinical	O
study	O
was	O
designed	O
to	O
demonstrate	O
that	O
there	O
are	O
no	O
clinically	O
meaningful	O
differences	O
in	O
the	O
efficacy	O
and	O
safety	O
profile	O
of	O
PF-06439535	O
(	O
a	O
bevacizumab	O
biosimilar	O
)	O
as	O
compared	O
with	O
reference	O
bevacizumab	O
(	O
[P1]	O
Avastin	O
®	O
[P2]	O
)	O
sourced	O
from	O
the	O
EU	O
(	O
bevacizumab	O
-	O
EU	O
)	O
in	O
a	O
patient	O
population	O
for	O
which	O
reference	O
bevacizumab	O
is	O
indicated	O
.	O

When	O
[P1]	O
PF-06439535	O
[P2]	O
or	O
bevacizumab	O
-	O
EU	O
was	O
combined	O
with	O
paclitaxel	O
and	O
carboplatin	O
in	O
the	O
first	O
-	O
line	O
treatment	O
of	O
advanced	O
non	O
-	O
squamous	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
,	O
we	O
identified	O
no	O
notable	O
differences	O
between	O
the	O
two	O
treatment	O
groups	O
with	O
respect	O
to	O
efficacy	O
,	O
safety	O
,	O
pharmacokinetics	O
,	O
or	O
immunogenicity	O
.	O

When	O
PF-06439535	O
or	O
[P1]	O
bevacizumab	O
[P2]	O
-	O
EU	O
was	O
combined	O
with	O
paclitaxel	O
and	O
carboplatin	O
in	O
the	O
first	O
-	O
line	O
treatment	O
of	O
advanced	O
non	O
-	O
squamous	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
,	O
we	O
identified	O
no	O
notable	O
differences	O
between	O
the	O
two	O
treatment	O
groups	O
with	O
respect	O
to	O
efficacy	O
,	O
safety	O
,	O
pharmacokinetics	O
,	O
or	O
immunogenicity	O
.	O

When	O
PF-06439535	O
or	O
bevacizumab	O
-	O
EU	O
was	O
combined	O
with	O
[P1]	O
paclitaxel	O
and	O
carboplatin	O
[P2]	O
in	O
the	O
first	O
-	O
line	O
treatment	O
of	O
advanced	O
non	O
-	O
squamous	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
,	O
we	O
identified	O
no	O
notable	O
differences	O
between	O
the	O
two	O
treatment	O
groups	O
with	O
respect	O
to	O
efficacy	O
,	O
safety	O
,	O
pharmacokinetics	O
,	O
or	O
immunogenicity	O
.	O

Patients	O
were	O
enrolled	O
by	O
study	O
investigators	O
and	O
randomized	O
in	O
a	O
1:1	O
ratio	O
to	O
receive	O
either	O
[P1]	O
PF-06439535	O
[P2]	O
plus	O
paclitaxel	O
and	O
carboplatin	O
or	O
bevacizumab	O
-	O
EU	O
plus	O
paclitaxel	O
and	O
carboplatin	O
for	O
4	B-arm_dosage
-	I-arm_dosage
6	I-arm_dosage
cycles	I-arm_dosage
,	O
followed	O
by	O
blinded	O
monotherapy	O
with	O
PF-06439535	O
or	O
bevacizumab	O
-	O
EU	O
as	O
previously	O
assigned	O
(	O
ESM	O
,	O
Fig	O
.	O

Patients	O
were	O
enrolled	O
by	O
study	O
investigators	O
and	O
randomized	O
in	O
a	O
1:1	O
ratio	O
to	O
receive	O
either	O
PF-06439535	O
plus	O
[P1]	O
paclitaxel	O
and	O
carboplatin	O
[P2]	O
or	O
bevacizumab	O
-	O
EU	O
plus	O
paclitaxel	O
and	O
carboplatin	O
for	O
4	B-arm_dosage
-	I-arm_dosage
6	I-arm_dosage
cycles	I-arm_dosage
,	O
followed	O
by	O
blinded	O
monotherapy	O
with	O
PF-06439535	O
or	O
bevacizumab	O
-	O
EU	O
as	O
previously	O
assigned	O
(	O
ESM	O
,	O
Fig	O
.	O

Patients	O
were	O
enrolled	O
by	O
study	O
investigators	O
and	O
randomized	O
in	O
a	O
1:1	O
ratio	O
to	O
receive	O
either	O
PF-06439535	O
plus	O
paclitaxel	O
and	O
carboplatin	O
or	O
[P1]	O
bevacizumab	O
[P2]	O
-	O
EU	O
plus	O
paclitaxel	O
and	O
carboplatin	O
for	O
4	O
-	O
6	O
cycles	O
,	O
followed	O
by	O
blinded	O
monotherapy	O
with	O
PF-06439535	O
or	O
bevacizumab	O
-	O
EU	O
as	O
previously	O
assigned	O
(	O
ESM	O
,	O
Fig	O
.	O

Patients	O
were	O
enrolled	O
by	O
study	O
investigators	O
and	O
randomized	O
in	O
a	O
1:1	O
ratio	O
to	O
receive	O
either	O
PF-06439535	O
plus	O
paclitaxel	O
and	O
carboplatin	O
or	O
bevacizumab	O
-	O
EU	O
plus	O
[P1]	O
paclitaxel	O
and	O
carboplatin	O
[P2]	O
for	O
4	O
-	O
6	O
cycles	O
,	O
followed	O
by	O
blinded	O
monotherapy	O
with	O
PF-06439535	O
or	O
bevacizumab	O
-	O
EU	O
as	O
previously	O
assigned	O
(	O
ESM	O
,	O
Fig	O
.	O

Patients	O
were	O
enrolled	O
by	O
study	O
investigators	O
and	O
randomized	O
in	O
a	O
1:1	O
ratio	O
to	O
receive	O
either	O
PF-06439535	O
plus	O
paclitaxel	O
and	O
carboplatin	O
or	O
bevacizumab	O
-	O
EU	O
plus	O
paclitaxel	O
and	O
carboplatin	O
for	O
4	O
-	O
6	O
cycles	O
,	O
followed	O
by	O
blinded	O
monotherapy	O
with	O
[P1]	O
PF-06439535	O
[P2]	O
or	O
bevacizumab	O
-	O
EU	O
as	O
previously	O
assigned	O
(	O
ESM	O
,	O
Fig	O
.	O

Patients	O
were	O
enrolled	O
by	O
study	O
investigators	O
and	O
randomized	O
in	O
a	O
1:1	O
ratio	O
to	O
receive	O
either	O
PF-06439535	O
plus	O
paclitaxel	O
and	O
carboplatin	O
or	O
bevacizumab	O
-	O
EU	O
plus	O
paclitaxel	O
and	O
carboplatin	O
for	O
4	O
-	O
6	O
cycles	O
,	O
followed	O
by	O
blinded	O
monotherapy	O
with	O
PF-06439535	O
or	O
[P1]	O
bevacizumab	O
[P2]	O
-	O
EU	O
as	O
previously	O
assigned	O
(	O
ESM	O
,	O
Fig	O
.	O

On	O
treatment	O
days	O
when	O
[P1]	O
PF-06439535	O
[P2]	O
or	O
bevacizumab	O
-	O
EU	O
was	O
administered	O
in	O
combination	O
with	O
chemotherapy	O
,	O
the	O
order	O
of	O
administration	O
was	O
paclitaxel	O
,	O
carboplatin	O
,	O
and	O
PF-06439535	O
or	O
bevacizumab	O
-	O
EU	O
.	O

On	O
treatment	O
days	O
when	O
PF-06439535	O
or	O
[P1]	O
bevacizumab	O
-	O
EU	O
[P2]	O
was	O
administered	O
in	O
combination	O
with	O
chemotherapy	O
,	O
the	O
order	O
of	O
administration	O
was	O
paclitaxel	O
,	O
carboplatin	O
,	O
and	O
PF-06439535	O
or	O
bevacizumab	O
-	O
EU	O
.	O

On	O
treatment	O
days	O
when	O
PF-06439535	O
or	O
bevacizumab	O
-	O
EU	O
was	O
administered	O
in	O
combination	O
with	O
chemotherapy	O
,	O
the	O
order	O
of	O
administration	O
was	O
paclitaxel	O
,	O
carboplatin	O
,	O
and	O
PF-06439535	O
or	O
[P1]	O
bevacizumab	O
-	O
EU	O
[P2]	O
.	O

[P1]	O
Paclitaxel	O
[P2]	O
was	O
administered	O
at	O
an	O
initial	B-arm_dosage
dose	I-arm_dosage
of	I-arm_dosage
200	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
,	O
carboplatin	O
at	O
an	O
initial	B-arm_dosage
dose	I-arm_dosage
targeting	O
an	O
area	O
under	O
the	O
concentration	O
versus	O
time	O
curve	O
of	O
6.0	B-arm_dosage
mg/	I-arm_dosage
mL•min	I-arm_dosage
,	I-arm_dosage
and	O
PF-06439535	O
or	O
bevacizumab	O
-	O
EU	O
at	O
an	O
initial	B-arm_dosage
dose	I-arm_dosage
of	I-arm_dosage
15	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
kg	I-arm_dosage
.	O

Paclitaxel	O
was	O
administered	O
at	O
an	O
initial	B-arm_dosage
dose	I-arm_dosage
of	I-arm_dosage
200	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
,	O
[P1]	O
carboplatin	O
[P2]	O
at	O
an	O
initial	B-arm_dosage
dose	I-arm_dosage
targeting	O
an	O
area	O
under	O
the	O
concentration	O
versus	O
time	O
curve	O
of	O
6.0	B-arm_dosage
mg/	I-arm_dosage
mL•min	I-arm_dosage
,	I-arm_dosage
and	O
PF-06439535	O
or	O
bevacizumab	O
-	O
EU	O
at	O
an	O
initial	B-arm_dosage
dose	I-arm_dosage
of	I-arm_dosage
15	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
kg	I-arm_dosage
.	O

Paclitaxel	O
was	O
administered	O
at	O
an	O
initial	O
dose	O
of	O
200	O
mg	O
/	O
m	O
2	O
,	O
carboplatin	O
at	O
an	O
initial	O
dose	O
targeting	O
an	O
area	O
under	O
the	O
concentration	O
versus	O
time	O
curve	O
of	O
6.0	O
mg/	O
mL•min	O
,	O
and	O
[P1]	O
PF-06439535	O
[P2]	O
or	O
bevacizumab	O
-	O
EU	O
at	O
an	O
initial	O
dose	O
of	O
15	O
mg	O
/	O
kg	O
.	O

Paclitaxel	O
was	O
administered	O
at	O
an	O
initial	B-arm_dosage
dose	I-arm_dosage
of	I-arm_dosage
200	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
,	O
carboplatin	O
at	O
an	O
initial	B-arm_dosage
dose	I-arm_dosage
targeting	O
an	O
area	O
under	O
the	O
concentration	O
versus	O
time	O
curve	O
of	O
6.0	B-arm_dosage
mg/	I-arm_dosage
mL•min	I-arm_dosage
,	I-arm_dosage
and	O
PF-06439535	O
or	O
[P1]	O
bevacizumab	O
-	O
EU	O
[P2]	O
at	O
an	O
initial	B-arm_dosage
dose	I-arm_dosage
of	I-arm_dosage
15	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
kg	I-arm_dosage
.	O

No	O
dose	O
reductions	O
were	O
planned	O
for	O
[P1]	O
PF-06439535	O
[P2]	O
or	O
bevacizumab	O
-	O
EU	O
,	O
but	O
if	O
deemed	O
necessary	O
the	O
investigator	O
could	O
decrease	O
the	O
dose	O
to	O
7.5	O
mg	O
/	O
kg	O
after	O
discussion	O
with	O
the	O
sponsor	O
.	O

No	O
dose	O
reductions	O
were	O
planned	O
for	O
PF-06439535	O
or	O
[P1]	O
bevacizumab	O
-	O
EU	O
[P2]	O
,	O
but	O
if	O
deemed	O
necessary	O
the	O
investigator	O
could	O
decrease	O
the	O
dose	O
to	O
7.5	O
mg	O
/	O
kg	O
after	O
discussion	O
with	O
the	O
sponsor	O
.	O

After	O
chemotherapy	O
had	O
been	O
discontinued	O
,	O
[P1]	O
PF-06439535	O
[P2]	O
or	O
bevacizumab	O
-	O
EU	O
monotherapy	O
could	O
be	O
administered	O
until	O
disease	O
progression	O
(	O
defined	O
per	O
RECIST	O
1.1	O
)	O
,	O
unacceptable	O
toxicity	O
,	O
discretion	O
of	O
the	O
investigator	O
,	O
death	O
,	O
withdrawal	O
of	O
consent	O
,	O
or	O
the	O
end	O
of	O
the	O
study	O
,	O
whichever	O
came	O
first	O
.	O

After	O
chemotherapy	O
had	O
been	O
discontinued	O
,	O
PF-06439535	O
or	O
[P1]	O
bevacizumab	O
-	O
EU	O
[P2]	O
monotherapy	O
could	O
be	O
administered	O
until	O
disease	O
progression	O
(	O
defined	O
per	O
RECIST	O
1.1	O
)	O
,	O
unacceptable	O
toxicity	O
,	O
discretion	O
of	O
the	O
investigator	O
,	O
death	O
,	O
withdrawal	O
of	O
consent	O
,	O
or	O
the	O
end	O
of	O
the	O
study	O
,	O
whichever	O
came	O
first	O
.	O

The	O
dose	O
and	O
regimen	O
for	O
[P1]	O
PF-06439535	O
[P2]	O
and	O
bevacizumab	O
-	O
EU	O
were	O
chosen	O
to	O
be	O
consistent	O
with	O
the	O
product	O
labeling	O
of	O
bevacizumab	O
-	O
EU	O
.	O

The	O
dose	O
and	O
regimen	O
for	O
PF-06439535	O
and	O
[P1]	O
bevacizumab	O
-	O
EU	O
[P2]	O
were	O
chosen	O
to	O
be	O
consistent	O
with	O
the	O
product	O
labeling	O
of	O
bevacizumab	O
-	O
EU	O
.	O

The	O
dose	O
and	O
regimen	O
for	O
PF-06439535	O
and	O
bevacizumab	O
-	O
EU	O
were	O
chosen	O
to	O
be	O
consistent	O
with	O
the	O
product	O
labeling	O
of	O
[P1]	O
bevacizumab	O
-	O
EU	O
[P2]	O
.	O

This	O
endpoint	O
was	O
considered	O
sufficiently	O
sensitive	O
to	O
detect	O
differences	O
in	O
efficacy	O
between	O
[P1]	O
PF-06439535	O
[P2]	O
and	O
bevacizumab	O
-	O
EU	O
.	O

This	O
endpoint	O
was	O
considered	O
sufficiently	O
sensitive	O
to	O
detect	O
differences	O
in	O
efficacy	O
between	O
PF-06439535	O
and	O
[P1]	O
bevacizumab	O
[P2]	O
-	O
EU	O
.	O

Additional	O
secondary	O
endpoints	O
included	O
safety	O
,	O
peak	O
and	O
trough	O
[P1]	O
PF-06439535	O
[P2]	O
and	O
bevacizumab	O
-	O
EU	O
concentrations	O
at	O
selected	O
cycles	O
up	O
to	O
1	O
year	O
from	O
randomization	O
,	O
and	O
incidence	O
of	O
anti	O
-	O
drug	O
antibodies	O
(	O
ADAs	O
;	O

Additional	O
secondary	O
endpoints	O
included	O
safety	O
,	O
peak	O
and	O
trough	O
PF-06439535	O
and	O
[P1]	O
bevacizumab	O
[P2]	O
-	O
EU	O
concentrations	O
at	O
selected	O
cycles	O
up	O
to	O
1	O
year	O
from	O
randomization	O
,	O
and	O
incidence	O
of	O
anti	O
-	O
drug	O
antibodies	O
(	O
ADAs	O
;	O

Drug	O
concentrations	O
of	O
[P1]	O
PF-06439535	O
[P2]	O
and	O
bevacizumab	O
-	O
EU	O
were	O
determined	O
using	O
serum	O
samples	O
collected	O
at	O
prespecified	O
time	O
points	O
.	O

Drug	O
concentrations	O
of	O
PF-06439535	O
and	O
[P1]	O
bevacizumab	O
[P2]	O
-	O
EU	O
were	O
determined	O
using	O
serum	O
samples	O
collected	O
at	O
prespecified	O
time	O
points	O
.	O

The	O
estimated	O
ORR	O
risk	O
ratio	O
and	O
ORR	O
risk	O
difference	O
between	O
the	O
[P1]	O
PF-06439535	O
[P2]	O
and	O
bevacizumab	O
-	O
EU	O
groups	O
were	O
computed	O
,	O
along	O
with	O
asymptotic	O
two	O
-	O
sided	O
95	O
%	O
and	O
90	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
.	O

The	O
estimated	O
ORR	O
risk	O
ratio	O
and	O
ORR	O
risk	O
difference	O
between	O
the	O
PF-06439535	O
and	O
[P1]	O
bevacizumab	O
[P2]	O
-	O
EU	O
groups	O
were	O
computed	O
,	O
along	O
with	O
asymptotic	O
two	O
-	O
sided	O
95	O
%	O
and	O
90	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
.	O

The	O
estimated	O
ORR	O
risk	O
ratio	O
and	O
ORR	O
risk	O
difference	O
between	O
the	O
PF-06439535	O
and	O
bevacizumab	O
-	O
EU	O
[P1]	O
groups	O
[P2]	O
were	O
computed	O
,	O
along	O
with	O
asymptotic	O
two	O
-	O
sided	O
95	O
%	O
and	O
90	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
.	O

The	O
ORR	O
for	O
reference	O
[P1]	O
bevacizumab	O
plus	O
chemotherapy	O
[P2]	O
was	O
estimated	O
to	O
be	O
approximately	O
40	O
%	O
,	O
and	O
the	O
ORR	O
for	O
chemotherapy	O
alone	O
was	O
estimated	O
to	O
be	O
21	O
%	O
.	O

The	O
ORR	O
risk	O
ratio	O
for	O
[P1]	O
bevacizumab	O
plus	O
chemotherapy	O
[P2]	O
versus	O
chemotherapy	O
alone	O
was	O
2.17	O
(	O
95	O
%	O
CI	O
1.74	O
-	O
2.70	O
)	O
.	O

As	O
a	O
sensitivity	O
analysis	O
,	O
the	O
Miettinen	O
and	O
Nurminen	O
method	O
[	O
25	O
]	O
was	O
also	O
conducted	O
without	O
stratification	O
variables	O
using	O
the	O
per	O
-	O
protocol	O
(	O
PP	O
)	O
population	O
,	O
defined	O
as	O
all	O
patients	O
who	O
were	O
randomized	O
and	O
received	O
[P1]	O
PF-06439535	O
[P2]	O
or	O
bevacizumab	O
-	O
EU	O
as	O
planned	O
and	O
had	O
no	O
major	O
protocol	O
deviations	O
.	O

As	O
a	O
sensitivity	O
analysis	O
,	O
the	O
Miettinen	O
and	O
Nurminen	O
method	O
[	O
25	O
]	O
was	O
also	O
conducted	O
without	O
stratification	O
variables	O
using	O
the	O
per	O
-	O
protocol	O
(	O
PP	O
)	O
population	O
,	O
defined	O
as	O
all	O
patients	O
who	O
were	O
randomized	O
and	O
received	O
PF-06439535	O
or	O
[P1]	O
bevacizumab	O
[P2]	O
-	O
EU	O
as	O
planned	O
and	O
had	O
no	O
major	O
protocol	O
deviations	O
.	O

In	O
total	O
,	O
719	O
patients	O
were	O
assigned	O
to	O
[P1]	O
PF-06439535	O
plus	O
paclitaxel	O
[P2]	O
and	O
carboplatin	O
(	O
PF-06439535	O
group	O
;	O

In	O
total	O
,	O
719	O
patients	O
were	O
assigned	O
to	O
PF-06439535	O
plus	O
paclitaxel	O
and	O
carboplatin	O
(	O
[P1]	O
PF-06439535	O
group	O
[P2]	O
;	O

358	O
patients	O
)	O
or	O
[P1]	O
bevacizumab	O
-	O
EU	O
plus	O
paclitaxel	O
and	O
carboplatin	O
[P2]	O
(	O
bevacizumab	O
-	O
EU	O
group	O
;	O

358	O
patients	O
)	O
or	O
bevacizumab	O
-	O
EU	O
plus	O
paclitaxel	O
and	O
carboplatin	O
(	O
[P1]	O
bevacizumab	O
-	O
EU	O
group	O
[P2]	O
;	O

Of	O
these	O
,	O
714	O
patients	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
or	O
chemotherapy	O
and	O
were	O
included	O
in	O
the	O
safety	O
population	O
(	O
356	O
patients	O
in	O
the	O
[P1]	O
PF-06439535	O
group	O
[P2]	O
and	O
358	O
patients	O
in	O
the	O
bevacizumab	O
-	O
EU	O
group	O
)	O
.	O

Of	O
these	O
,	O
714	O
patients	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
or	O
chemotherapy	O
and	O
were	O
included	O
in	O
the	O
safety	O
population	O
(	O
356	O
patients	O
in	O
the	O
PF-06439535	O
group	O
and	O
358	O
patients	O
in	O
the	O
[P1]	O
bevacizumab	O
-	O
EU	O
group	O
[P2]	O
)	O
.	O

Among	O
the	O
714	O
patients	O
in	O
the	O
safety	O
population	O
,	O
the	O
primary	O
reason	O
for	O
discontinuation	O
of	O
[P1]	O
PF-06439535	O
[P2]	O
or	O
bevacizumab	O
-	O
EU	O
was	O
objective	O
disease	O
progression	O
or	O
relapse	O
(	O
176	O
[	O
49.4	O
%	O
]	O
patients	O
in	O
the	O
PF-06439535	O
group	O
and	O
207	O
[	O
57.8	O
%	O
]	O
patients	O
in	O
the	O
bevacizumab	O
-	O
EU	O
group	O
)	O
(	O
ESM	O
,	O
Table	O
S2	O
)	O
.	O

Among	O
the	O
714	O
patients	O
in	O
the	O
safety	O
population	O
,	O
the	O
primary	O
reason	O
for	O
discontinuation	O
of	O
PF-06439535	O
or	O
[P1]	O
bevacizumab	O
-	O
EU	O
[P2]	O
was	O
objective	O
disease	O
progression	O
or	O
relapse	O
(	O
176	O
[	O
49.4	O
%	O
]	O
patients	O
in	O
the	O
PF-06439535	O
group	O
and	O
207	O
[	O
57.8	O
%	O
]	O
patients	O
in	O
the	O
bevacizumab	O
-	O
EU	O
group	O
)	O
(	O
ESM	O
,	O
Table	O
S2	O
)	O
.	O

Among	O
the	O
714	O
patients	O
in	O
the	O
safety	O
population	O
,	O
the	O
primary	O
reason	O
for	O
discontinuation	O
of	O
PF-06439535	O
or	O
bevacizumab	O
-	O
EU	O
was	O
objective	O
disease	O
progression	O
or	O
relapse	O
(	O
176	O
[	O
49.4	O
%	O
]	O
patients	O
in	O
the	O
[P1]	O
PF-06439535	O
group	O
[P2]	O
and	O
207	O
[	O
57.8	O
%	O
]	O
patients	O
in	O
the	O
bevacizumab	O
-	O
EU	O
group	O
)	O
(	O
ESM	O
,	O
Table	O
S2	O
)	O
.	O

Among	O
the	O
714	O
patients	O
in	O
the	O
safety	O
population	O
,	O
the	O
primary	O
reason	O
for	O
discontinuation	O
of	O
PF-06439535	O
or	O
bevacizumab	O
-	O
EU	O
was	O
objective	O
disease	O
progression	O
or	O
relapse	O
(	O
176	O
[	O
49.4	O
%	O
]	O
patients	O
in	O
the	O
PF-06439535	O
group	O
and	O
207	O
[	O
57.8	O
%	O
]	O
patients	O
in	O
the	O
[P1]	O
bevacizumab	O
-	O
EU	O
group	O
[P2]	O
)	O
(	O
ESM	O
,	O
Table	O
S2	O
)	O
.	O

Including	O
the	O
survival	O
follow	O
-	O
up	O
period	O
,	O
the	O
most	O
frequent	O
reason	O
for	O
discontinuation	O
from	O
the	O
study	O
was	O
death	O
(	O
136	O
[	O
38.2	O
%	O
]	O
patients	O
in	O
the	O
[P1]	O
PF-06439535	O
group	O
[P2]	O
and	O
138	O
[	O
38.5	O
%	O
]	O
patients	O
in	O
the	O
bevacizumab	O
-	O
EU	O
group	O
)	O
.	O

Including	O
the	O
survival	O
follow	O
-	O
up	O
period	O
,	O
the	O
most	O
frequent	O
reason	O
for	O
discontinuation	O
from	O
the	O
study	O
was	O
death	O
(	O
136	O
[	O
38.2	O
%	O
]	O
patients	O
in	O
the	O
PF-06439535	O
group	O
and	O
138	O
[	O
38.5	O
%	O
]	O
patients	O
in	O
the	O
[P1]	O
bevacizumab	O
-	O
EU	O
group	O
[P2]	O
)	O
.	O

The	O
mean	O
(	O
standard	O
deviation	O
)	O
duration	O
of	O
treatment	O
was	O
35.2	O
(	O
27.19	O
)	O
weeks	O
in	O
the	O
[P1]	O
PF-06439535	O
group	O
[P2]	O
and	O
34.9	O
(	O
25.96	O
)	O
weeks	O
in	O
the	O
bevacizumab	O
-	O
EU	O
group	O
.	O

The	O
mean	O
(	O
standard	O
deviation	O
)	O
duration	O
of	O
treatment	O
was	O
35.2	O
(	O
27.19	O
)	O
weeks	O
in	O
the	O
PF-06439535	O
group	O
and	O
34.9	O
(	O
25.96	O
)	O
weeks	O
in	O
the	O
[P1]	O
bevacizumab	O
-	O
EU	O
group	O
[P2]	O
.	O

In	O
the	O
[P1]	O
PF-06439535	O
group	O
[P2]	O
,	O
the	O
median	O
number	O
of	O
cycles	O
of	O
PF-06439535	O
treatment	O
was	O
11.0	O
(	O
range	O
1	O
-	O
41	O
)	O
,	O
with	O
6.0	O
cycles	O
(	O
range	O
1	O
-	O
6	O
cycles	O
)	O
of	O
paclitaxel	O
treatment	O
and	O
6.0	O
cycles	O
(	O
range	O
1	O
-	O
6	O
cycles	O
)	O
of	O
carboplatin	O
treatment	O
.	O

In	O
the	O
PF-06439535	O
group	O
,	O
the	O
median	O
number	O
of	O
cycles	O
of	O
[P1]	O
PF-06439535	O
treatment	O
[P2]	O
was	O
11.0	O
(	O
range	O
1	O
-	O
41	O
)	O
,	O
with	O
6.0	O
cycles	O
(	O
range	O
1	O
-	O
6	O
cycles	O
)	O
of	O
paclitaxel	O
treatment	O
and	O
6.0	O
cycles	O
(	O
range	O
1	O
-	O
6	O
cycles	O
)	O
of	O
carboplatin	O
treatment	O
.	O

In	O
the	O
[P1]	O
bevacizumab	O
-	O
EU	O
group	O
[P2]	O
,	O
the	O
median	O
number	O
of	O
cycles	O
of	O
bevacizumab	O
-	O
EU	O
treatment	O
was	O
11.0	O
(	O
range	O
1	O
-	O
38	O
)	O
,	O
with	O
6.0	O
cycles	O
(	O
range	O
1	O
-	O
6	O
cycles	O
)	O
of	O
paclitaxel	O
treatment	O
and	O
6.0	O
cycles	O
(	O
range	O
1	O
-	O
6	O
cycles	O
)	O
of	O
carboplatin	O
treatment	O
.	O

In	O
the	O
bevacizumab	O
-	O
EU	O
group	O
,	O
the	O
median	O
number	O
of	O
cycles	O
of	O
[P1]	O
bevacizumab	O
-	O
EU	O
[P2]	O
treatment	O
was	O
11.0	O
(	O
range	O
1	O
-	O
38	O
)	O
,	O
with	O
6.0	O
cycles	O
(	O
range	O
1	O
-	O
6	O
cycles	O
)	O
of	O
paclitaxel	O
treatment	O
and	O
6.0	O
cycles	O
(	O
range	O
1	O
-	O
6	O
cycles	O
)	O
of	O
carboplatin	O
treatment	O
.	O

Thus	O
,	O
similarity	O
between	O
[P1]	O
PF-06439535	O
[P2]	O
and	O
bevacizumab	O
-	O
EU	O
was	O
demonstrated	O
for	O
ORR	O
,	O
based	O
on	O
the	O
pre	O
-	O
specified	O
criteria	O
for	O
each	O
of	O
the	O
three	O
health	O
authorities	O
.	O

Thus	O
,	O
similarity	O
between	O
PF-06439535	O
and	O
[P1]	O
bevacizumab	O
-	O
EU	O
[P2]	O
was	O
demonstrated	O
for	O
ORR	O
,	O
based	O
on	O
the	O
pre	O
-	O
specified	O
criteria	O
for	O
each	O
of	O
the	O
three	O
health	O
authorities	O
.	O

a	O
One	O
patient	O
received	O
paclitaxel	O
and	O
carboplatin	O
but	O
withdrew	O
before	O
receiving	O
[P1]	O
PF-06439535	O
[P2]	O
.	O

c	O
The	O
most	O
frequently	O
reported	O
reason	O
for	O
patients	O
not	O
being	O
included	O
in	O
the	O
PP	O
population	O
was	O
due	O
to	O
being	O
randomized	O
but	O
never	O
dosed	O
with	O
[P1]	O
PF-06439535	O
[P2]	O
or	O
bevacizumab	O
-	O
EU	O
(	O
3	O
[	O
0.8	O
%	O
]	O
patients	O
in	O
the	O
PF-06439535	O
group	O
and	O
3	O
[	O
0.8	O
%	O
]	O
patients	O
in	O
the	O
bevacizumab	O
-	O
EU	O
group	O
)	O
.	O

c	O
The	O
most	O
frequently	O
reported	O
reason	O
for	O
patients	O
not	O
being	O
included	O
in	O
the	O
PP	O
population	O
was	O
due	O
to	O
being	O
randomized	O
but	O
never	O
dosed	O
with	O
PF-06439535	O
or	O
[P1]	O
bevacizumab	O
-	O
EU	O
[P2]	O
(	O
3	O
[	O
0.8	O
%	O
]	O
patients	O
in	O
the	O
PF-06439535	O
group	O
and	O
3	O
[	O
0.8	O
%	O
]	O
patients	O
in	O
the	O
bevacizumab	O
-	O
EU	O
group	O
)	O
.	O

c	O
The	O
most	O
frequently	O
reported	O
reason	O
for	O
patients	O
not	O
being	O
included	O
in	O
the	O
PP	O
population	O
was	O
due	O
to	O
being	O
randomized	O
but	O
never	O
dosed	O
with	O
PF-06439535	O
or	O
bevacizumab	O
-	O
EU	O
(	O
3	O
[	O
0.8	O
%	O
]	O
patients	O
in	O
the	O
[P1]	O
PF-06439535	O
group	O
[P2]	O
and	O
3	O
[	O
0.8	O
%	O
]	O
patients	O
in	O
the	O
bevacizumab	O
-	O
EU	O
group	O
)	O
.	O

c	O
The	O
most	O
frequently	O
reported	O
reason	O
for	O
patients	O
not	O
being	O
included	O
in	O
the	O
PP	O
population	O
was	O
due	O
to	O
being	O
randomized	O
but	O
never	O
dosed	O
with	O
PF-06439535	O
or	O
bevacizumab	O
-	O
EU	O
(	O
3	O
[	O
0.8	O
%	O
]	O
patients	O
in	O
the	O
PF-06439535	O
group	O
and	O
3	O
[	O
0.8	O
%	O
]	O
patients	O
in	O
the	O
[P1]	O
bevacizumab	O
-	O
EU	O
group	O
[P2]	O
)	O
.	O

[P1]	O
Bevacizumab	O
-	O
EU	O
reference	O
bevacizumab	O
[P2]	O
sourced	O
from	O
the	O
European	O
Union	O
,	O
COPD	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
ITT	O
intent	O
-	O
to	O
-	O
treat	O
,	O
ORR	O
objective	O
response	O
rate	O
,	O
PK	O
pharmacokinetics	O
,	O
PP	O
per	O
-	O
protocol	O

The	O
most	O
frequently	O
reported	O
grade	O
3	O
or	O
higher	O
TEAE	O
of	O
special	O
interest	O
was	O
hypertension	O
(	O
34	O
[	O
9.6	O
%	O
]	O
patients	O
in	O
the	O
[P1]	O
PF-06439535	O
group	O
[P2]	O
and	O
32	O
[	O
8.9	O
%	O
]	O
patients	O
in	O
the	O
bevacizumab	O
-	O
EU	O
group	O
)	O
(	O
Table	O
3	O
)	O
.	O

The	O
most	O
frequently	O
reported	O
grade	O
3	O
or	O
higher	O
TEAE	O
of	O
special	O
interest	O
was	O
hypertension	O
(	O
34	O
[	O
9.6	O
%	O
]	O
patients	O
in	O
the	O
PF-06439535	O
group	O
and	O
32	O
[	O
8.9	O
%	O
]	O
patients	O
in	O
the	O
[P1]	O
bevacizumab	O
-	O
EU	O
group	O
[P2]	O
)	O
(	O
Table	O
3	O
)	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
in	O
patients	O
with	O
advanced	O
nonsquamous	O
NSCLC	O
demonstrated	O
similarity	O
between	O
[P1]	O
PF-06439535	O
[P2]	O
and	O
bevacizumab	O
-	O
EU	O
in	O
terms	O
of	O
the	O
primary	O
efficacy	O
endpoint	O
of	O
ORR	O
,	O
when	O
each	O
was	O
administered	O
in	O
combination	O
with	O
paclitaxel	O
and	O
carboplatin	O
as	O
first	O
-	O
line	O
treatment	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
in	O
patients	O
with	O
advanced	O
nonsquamous	O
NSCLC	O
demonstrated	O
similarity	O
between	O
PF-06439535	O
and	O
[P1]	O
bevacizumab	O
[P2]	O
-	O
EU	O
in	O
terms	O
of	O
the	O
primary	O
efficacy	O
endpoint	O
of	O
ORR	O
,	O
when	O
each	O
was	O
administered	O
in	O
combination	O
with	O
paclitaxel	O
and	O
carboplatin	O
as	O
first	O
-	O
line	O
treatment	O
.	O

These	O
results	O
confirm	O
the	O
similarity	O
demonstrated	O
in	O
earlier	O
analytical	O
,	O
nonclinical	O
,	O
and	O
clinical	O
studies	O
of	O
[P1]	O
PF-06439535	O
[P2]	O
and	O
reference	O
bevacizumab	O
[	O
20,21	O
]	O
.	O

These	O
results	O
confirm	O
the	O
similarity	O
demonstrated	O
in	O
earlier	O
analytical	O
,	O
nonclinical	O
,	O
and	O
clinical	O
studies	O
of	O
PF-06439535	O
and	O
reference	O
[P1]	O
bevacizumab	O
[P2]	O
[	O
20,21	O
]	O
.	O